AU2015238296B2 - Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors - Google Patents
Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors Download PDFInfo
- Publication number
- AU2015238296B2 AU2015238296B2 AU2015238296A AU2015238296A AU2015238296B2 AU 2015238296 B2 AU2015238296 B2 AU 2015238296B2 AU 2015238296 A AU2015238296 A AU 2015238296A AU 2015238296 A AU2015238296 A AU 2015238296A AU 2015238296 B2 AU2015238296 B2 AU 2015238296B2
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- 6alkyl
- hydrogen
- formula
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC*C(N(*)C(C)(C)*O)=O Chemical compound CCCC*C(N(*)C(C)(C)*O)=O 0.000 description 4
- CTTLTFNUKPOHIF-UHFFFAOYSA-N CC(C)c(cc1)ccc1C(COc(cccc1)c1O)=O Chemical compound CC(C)c(cc1)ccc1C(COc(cccc1)c1O)=O CTTLTFNUKPOHIF-UHFFFAOYSA-N 0.000 description 1
- HCPADIXZPKHJGZ-UHFFFAOYSA-N CC(C)c1c(CCN)cc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 Chemical compound CC(C)c1c(CCN)cc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 HCPADIXZPKHJGZ-UHFFFAOYSA-N 0.000 description 1
- WNPVGMOUOAKDEM-UHFFFAOYSA-N CC(C)c1ccc(C2Oc(ccc(C)c3)c3NC2=C)cc1 Chemical compound CC(C)c1ccc(C2Oc(ccc(C)c3)c3NC2=C)cc1 WNPVGMOUOAKDEM-UHFFFAOYSA-N 0.000 description 1
- PCYPVDBBWFOZJO-UHFFFAOYSA-N CC(C)c1ccc(COc(c(F)c2)cc(F)c2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 Chemical compound CC(C)c1ccc(COc(c(F)c2)cc(F)c2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 PCYPVDBBWFOZJO-UHFFFAOYSA-N 0.000 description 1
- MDRAHNNUJHTLBN-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)cc(C#N)c2Br)cc1 Chemical compound CC(C)c1ccc(COc(cc2)cc(C#N)c2Br)cc1 MDRAHNNUJHTLBN-UHFFFAOYSA-N 0.000 description 1
- KPOSZCKTUSSTIQ-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)ccc2-c2c(C(N(CCO)CC3)=O)[n]3nc2-c2ccnc3c2cc[nH]3)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2-c2c(C(N(CCO)CC3)=O)[n]3nc2-c2ccnc3c2cc[nH]3)cc1 KPOSZCKTUSSTIQ-UHFFFAOYSA-N 0.000 description 1
- HQTFIBNJMVJVNH-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)ccc2-c2c(C(N)=O)[n](C)nc2-c2ccncc2)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2-c2c(C(N)=O)[n](C)nc2-c2ccncc2)cc1 HQTFIBNJMVJVNH-UHFFFAOYSA-N 0.000 description 1
- XIUIRYCCEJKLGP-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccnc(N)n2)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccnc(N)n2)cc1 XIUIRYCCEJKLGP-UHFFFAOYSA-N 0.000 description 1
- NFWSJBGZFRMFIX-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)ccc2-c2c(C(OC)=O)[n](CCN)nc2-c2ccnc(C(OC)=O)c2)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2-c2c(C(OC)=O)[n](CCN)nc2-c2ccnc(C(OC)=O)c2)cc1 NFWSJBGZFRMFIX-UHFFFAOYSA-N 0.000 description 1
- MONDUYFDTJIXRU-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)ccc2-c2c(CN(CC(NC)=O)CC3)[n]3nc2-c2ccncn2)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2-c2c(CN(CC(NC)=O)CC3)[n]3nc2-c2ccncn2)cc1 MONDUYFDTJIXRU-UHFFFAOYSA-N 0.000 description 1
- SIIVRYQORCURPJ-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)ccc2-c2c(CN(CCN)CC3)[n]3nc2-c2ccncc2)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2-c2c(CN(CCN)CC3)[n]3nc2-c2ccncc2)cc1 SIIVRYQORCURPJ-UHFFFAOYSA-N 0.000 description 1
- GUUZGVOODFRSDC-UHFFFAOYSA-N CC(C)c1ccc(COc(cc2)ccc2-c2c(CN(CCO)CC3)[n]3nc2-c2ccncn2)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2-c2c(CN(CCO)CC3)[n]3nc2-c2ccncn2)cc1 GUUZGVOODFRSDC-UHFFFAOYSA-N 0.000 description 1
- YGNZWLOYOQKWMM-GHFXIQBCSA-N CC(C)c1ccc(COc(cc2)ccc2/C(/C(c2ccncc2)=N)=C2/NCCN(CCO)C2O)cc1 Chemical compound CC(C)c1ccc(COc(cc2)ccc2/C(/C(c2ccncc2)=N)=C2/NCCN(CCO)C2O)cc1 YGNZWLOYOQKWMM-GHFXIQBCSA-N 0.000 description 1
- CVESAHGLOMXGCV-UHFFFAOYSA-N CC(C)c1ccc(COc(ccc(-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)c2)c2Cl)cc1 Chemical compound CC(C)c1ccc(COc(ccc(-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)c2)c2Cl)cc1 CVESAHGLOMXGCV-UHFFFAOYSA-N 0.000 description 1
- IEQJEFZCZYTQJR-UHFFFAOYSA-N CC(C)c1ccc(COc(ccc(B2OC(C)(C)C(C)(C)O2)c2)c2C#N)cc1 Chemical compound CC(C)c1ccc(COc(ccc(B2OC(C)(C)C(C)(C)O2)c2)c2C#N)cc1 IEQJEFZCZYTQJR-UHFFFAOYSA-N 0.000 description 1
- FYQXXCVZCSNUOD-UHFFFAOYSA-N CC(C)c1ccc(COc2ncc(B3OC(C)(C)C(C)(C)O3)cc2)cc1 Chemical compound CC(C)c1ccc(COc2ncc(B3OC(C)(C)C(C)(C)O3)cc2)cc1 FYQXXCVZCSNUOD-UHFFFAOYSA-N 0.000 description 1
- LARABSXOCXDQPD-UHFFFAOYSA-N CC(COc(cc1)ccc1-c1c(C(N(C)C(CO)C2)=O)[n]2nc1-c1ccncc1)=C Chemical compound CC(COc(cc1)ccc1-c1c(C(N(C)C(CO)C2)=O)[n]2nc1-c1ccncc1)=C LARABSXOCXDQPD-UHFFFAOYSA-N 0.000 description 1
- BICZJRAGTCRORZ-UHFFFAOYSA-N CC1(C)OB(c(cc2)ccc2O)OC1(C)C Chemical compound CC1(C)OB(c(cc2)ccc2O)OC1(C)C BICZJRAGTCRORZ-UHFFFAOYSA-N 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N CC1(C)OBOC1(C)C Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- WVCYNSGDNJHYRY-UHFFFAOYSA-N CC1(C)OC(CN(CC[n](c2c3-c(cc4)ccc4O)nc3-c3ccncn3)C2=O)CO1 Chemical compound CC1(C)OC(CN(CC[n](c2c3-c(cc4)ccc4O)nc3-c3ccncn3)C2=O)CO1 WVCYNSGDNJHYRY-UHFFFAOYSA-N 0.000 description 1
- OBGJIVWWKAXFJP-UHFFFAOYSA-N CCCN(CC[n](c1c2-c(cc3)cc(CC4)c3OC4c3ccc(C(C)C)cc3)nc2-c2ccncc2)C1=O Chemical compound CCCN(CC[n](c1c2-c(cc3)cc(CC4)c3OC4c3ccc(C(C)C)cc3)nc2-c2ccncc2)C1=O OBGJIVWWKAXFJP-UHFFFAOYSA-N 0.000 description 1
- SLNWXRIUECOUPW-UHFFFAOYSA-N CCCN(CC[n](c1c2-c(cc3)ccc3OCc3ccc(C(C)CC)cc3)nc2-c2ccncc2)C1=O Chemical compound CCCN(CC[n](c1c2-c(cc3)ccc3OCc3ccc(C(C)CC)cc3)nc2-c2ccncc2)C1=O SLNWXRIUECOUPW-UHFFFAOYSA-N 0.000 description 1
- YBWCCCNRKLQQFL-UHFFFAOYSA-N CCCN(CC[n](c1c2-c(cc3C)cc(C)c3OCc3ccc(C(C)C)cc3)nc2-c2ccncc2)C1=O Chemical compound CCCN(CC[n](c1c2-c(cc3C)cc(C)c3OCc3ccc(C(C)C)cc3)nc2-c2ccncc2)C1=O YBWCCCNRKLQQFL-UHFFFAOYSA-N 0.000 description 1
- SYUUDIGYEPQMHE-UHFFFAOYSA-N CCC[n](c(C(OCC)=O)c1-c(cc2)ccc2OCc2ccc(C(C)C)cc2)nc1-c1ccncn1 Chemical compound CCC[n](c(C(OCC)=O)c1-c(cc2)ccc2OCc2ccc(C(C)C)cc2)nc1-c1ccncn1 SYUUDIGYEPQMHE-UHFFFAOYSA-N 0.000 description 1
- XNLOLBZCKDUYDI-UHFFFAOYSA-N CCC[n]1nc(C)c(-c2ccc(C)cc2)c1C(C)=O Chemical compound CCC[n]1nc(C)c(-c2ccc(C)cc2)c1C(C)=O XNLOLBZCKDUYDI-UHFFFAOYSA-N 0.000 description 1
- XBADFVKKKBCDDU-UHFFFAOYSA-N CCOC(c([nH]nc1-c2ccnc(N)c2)c1-c(cc1)ccc1OCc1ccc(C(C)C)cc1)=O Chemical compound CCOC(c([nH]nc1-c2ccnc(N)c2)c1-c(cc1)ccc1OCc1ccc(C(C)C)cc1)=O XBADFVKKKBCDDU-UHFFFAOYSA-N 0.000 description 1
- UFIVYANDEPWNIH-UHFFFAOYSA-N COC(c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1)=O Chemical compound COC(c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1)=O UFIVYANDEPWNIH-UHFFFAOYSA-N 0.000 description 1
- CFFDIFBUVOLGKJ-UHFFFAOYSA-N C[Si+](C)(C)c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 Chemical compound C[Si+](C)(C)c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 CFFDIFBUVOLGKJ-UHFFFAOYSA-N 0.000 description 1
- XZPCLHLVRRSKBY-UHFFFAOYSA-N Cc([n](CCN)nc1-c2ccncn2)c1-c1ccc(C)cc1 Chemical compound Cc([n](CCN)nc1-c2ccncn2)c1-c1ccc(C)cc1 XZPCLHLVRRSKBY-UHFFFAOYSA-N 0.000 description 1
- PVDRGQQYHUDMAO-UHFFFAOYSA-N N#CC1(CC1)c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 Chemical compound N#CC1(CC1)c1ccc(COc(cc2)ccc2-c2c(C(NCC3)=O)[n]3nc2-c2ccncc2)cc1 PVDRGQQYHUDMAO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14161950 | 2014-03-27 | ||
| EP14161950.2 | 2014-03-27 | ||
| PCT/EP2015/056498 WO2015144799A1 (en) | 2014-03-27 | 2015-03-26 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015238296A1 AU2015238296A1 (en) | 2016-09-08 |
| AU2015238296B2 true AU2015238296B2 (en) | 2018-10-18 |
Family
ID=50389872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015238296A Active AU2015238296B2 (en) | 2014-03-27 | 2015-03-26 | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10280170B2 (enExample) |
| EP (1) | EP3129376B1 (enExample) |
| JP (1) | JP6522646B2 (enExample) |
| KR (1) | KR102455519B1 (enExample) |
| CN (1) | CN106164076B (enExample) |
| AU (1) | AU2015238296B2 (enExample) |
| BR (1) | BR112016022105B1 (enExample) |
| CA (1) | CA2940918C (enExample) |
| EA (1) | EA032255B1 (enExample) |
| ES (1) | ES2715676T3 (enExample) |
| IL (1) | IL247947B (enExample) |
| MX (1) | MX367914B (enExample) |
| WO (1) | WO2015144799A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6116782B1 (ja) * | 2015-08-28 | 2017-04-19 | 積水メディカル株式会社 | ベンジル化合物 |
| TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| WO2019233456A1 (zh) * | 2018-06-08 | 2019-12-12 | 贝达药业股份有限公司 | Erk抑制剂及其应用 |
| KR20210114001A (ko) * | 2019-01-11 | 2021-09-17 | 시오노기 앤드 컴파니, 리미티드 | Mgat2 저해 활성을 갖는 다이하이드로피라졸로피라지논 유도체 |
| JP7068743B2 (ja) * | 2019-01-11 | 2022-05-17 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114315866B (zh) * | 2020-09-30 | 2023-10-31 | 烟台药物研究所 | 一种盐酸左旋咪唑的合成方法 |
| TW202229282A (zh) * | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022127756A1 (en) * | 2020-12-15 | 2022-06-23 | Gritscience Biopharmaceuticals Co., Ltd. | Compounds as casein kinase inhibitors |
| CN114957259A (zh) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | 氰基取代的芳香双环类化合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058176A2 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| US7662826B2 (en) | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
| CA2494700C (en) | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| AU2008335151A1 (en) * | 2007-12-12 | 2009-06-18 | E. I. Du Pont De Nemours And Company | Fungicidal bicyclic pyrazoles |
| EP2235020A1 (en) | 2007-12-21 | 2010-10-06 | Wyeth LLC | Pyrazolo [1,5-a] pyrimidine compounds |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| KR101238585B1 (ko) | 2008-04-07 | 2013-02-28 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| EP2271645A1 (en) * | 2008-04-07 | 2011-01-12 | Irm Llc | Compounds and compositions as kinase inhibitors |
| EA019507B1 (ru) * | 2008-05-13 | 2014-04-30 | Айрм Ллк | Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы |
| CN102459264A (zh) * | 2009-05-27 | 2012-05-16 | 雅培制药有限公司 | 激酶活性的嘧啶抑制剂 |
| EP2434960A1 (en) | 2009-05-28 | 2012-04-04 | Cook Medical Technologies LLC | Tacking device and methods of deployment |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2013017989A1 (en) * | 2011-08-02 | 2013-02-07 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
-
2015
- 2015-03-26 CN CN201580016470.XA patent/CN106164076B/zh active Active
- 2015-03-26 WO PCT/EP2015/056498 patent/WO2015144799A1/en not_active Ceased
- 2015-03-26 CA CA2940918A patent/CA2940918C/en active Active
- 2015-03-26 US US15/129,582 patent/US10280170B2/en active Active
- 2015-03-26 AU AU2015238296A patent/AU2015238296B2/en active Active
- 2015-03-26 ES ES15713436T patent/ES2715676T3/es active Active
- 2015-03-26 JP JP2016559326A patent/JP6522646B2/ja active Active
- 2015-03-26 EP EP15713436.2A patent/EP3129376B1/en active Active
- 2015-03-26 BR BR112016022105-2A patent/BR112016022105B1/pt active IP Right Grant
- 2015-03-26 MX MX2016012668A patent/MX367914B/es active IP Right Grant
- 2015-03-26 KR KR1020167028572A patent/KR102455519B1/ko active Active
- 2015-03-26 EA EA201691930A patent/EA032255B1/ru not_active IP Right Cessation
-
2016
- 2016-09-21 IL IL247947A patent/IL247947B/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058176A2 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2715676T3 (es) | 2019-06-05 |
| IL247947B (en) | 2019-03-31 |
| JP2017508779A (ja) | 2017-03-30 |
| CA2940918A1 (en) | 2015-10-01 |
| CN106164076A (zh) | 2016-11-23 |
| KR102455519B1 (ko) | 2022-10-14 |
| US10280170B2 (en) | 2019-05-07 |
| US20170174690A1 (en) | 2017-06-22 |
| EA032255B1 (ru) | 2019-04-30 |
| MX2016012668A (es) | 2016-12-14 |
| MX367914B (es) | 2019-09-11 |
| KR20160137576A (ko) | 2016-11-30 |
| CN106164076B (zh) | 2019-03-26 |
| EP3129376A1 (en) | 2017-02-15 |
| BR112016022105B1 (pt) | 2023-01-31 |
| WO2015144799A1 (en) | 2015-10-01 |
| AU2015238296A1 (en) | 2016-09-08 |
| BR112016022105A2 (enExample) | 2017-08-15 |
| CA2940918C (en) | 2023-10-24 |
| JP6522646B2 (ja) | 2019-05-29 |
| EP3129376B1 (en) | 2018-12-26 |
| EA201691930A1 (ru) | 2017-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015238296B2 (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors | |
| EP3472147B1 (en) | Azabenzimidazole derivatives as pi3k beta inhibitors | |
| CA3157361A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| AU2015239098B2 (en) | Macrocylic pyrimidine derivatives | |
| AU2015238298B2 (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors | |
| JP2017508779A5 (enExample) | ||
| CN109311846B (zh) | 作为nik抑制剂的新的6元杂芳族取代的氰基吲哚衍生物 | |
| KR102662373B1 (ko) | Nik 억제제로서의 신규 치환 아자인돌린 유도체 | |
| TW202110848A (zh) | 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用 | |
| EP3233862B1 (en) | Imidazopyridazine derivatives as pi3kbeta inhibitors | |
| KR20220137002A (ko) | 헤테로고리 화합물 및 그의 약제학적 조성물, 제조 방법, 중간체 및 용도 | |
| US20240368139A1 (en) | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof | |
| TW202045487A (zh) | Pd-l1拮抗劑化合物 | |
| CN107108633B (zh) | 作为PI3Kβ抑制剂的杂环基连接的咪唑并哒嗪衍生物 | |
| EP3472160B1 (en) | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as pi3k beta inhibitors | |
| WO2025193878A1 (en) | Kras inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |